Injecting MENOPUR^®

At Ferring, we understand that having to mix and administer your own medication may seem overwhelming, and increased stress and anxiety levels can potentially hinder your treatment. We want to make it as easy and stress-free as possible.

In a survey among members of RESOLVE, The National Infertility Association, patients who were prescribed multiple injection methods (needle and syringe plus pen) experienced higher levels of anxiety when handling, preparing, and injecting their medications.¹

When you use Ferring fertility products, injection via needle and syringe is the only method you need to learn so you can feel much more confident and relaxed as treatment proceeds.

MENOPUR^® is approved for reconstitution with the Q•Cap™ needle-free vial adapter and subcutaneous (SC) injection. To help you through this process, we’ve developed an easy-to-follow injection guides. Simply access the instructions below that match your doctor’s recommendation.

If you have any questions or concerns regarding your injections, don't hesitate to contact your doctor's office.

MENOPUR^® administered subcutaneously is indicated for the development of multiple follicles and pregnancy in the ovulatory patients participating in an ART program.

Important Safety Information

Only physicians thoroughly familiar with infertility treatment, including the risk of multiple births and adverse reactions, should prescribe MENOPUR^®. MENOPUR^®, like all gonadotropins, is a potent substance capable of causing mild to severe adverse reactions, including OHSS (overall incidence 3.8%), with or without pulmonary or vascular complications, in women undergoing therapy for infertility. MENOPUR^® is contraindicated in women who have a high FSH level indicating primary ovarian failure; uncontrolled thyroid and adrenal dysfunction; an organic intracranial lesion such as a pituitary tumor; sex hormone dependent tumors of the reproductive tract and accessory organs; abnormal uterine bleeding of undetermined origin; ovarian cysts or enlargement not due to polycystic ovary syndrome; prior hypersensitivity to menotropins or MENOPUR^®. MENOPUR^® is not indicated in women who are pregnant. There are limited human data on the effects of menotropins when administered during pregnancy.

Click here to see Full Prescribing Information for MENOPUR^®.

Reference: 1. Patient Assessment of Infertility Treatment Administration. Results of An Online Patient Survey. Bethesda, Md: RESOLVE: The National Fertility Association; 2006.

Previous: MENOPUR®

Next: MENOPUR® FAQs